NTEC - Intec Pharma Ltd.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
5.60
-0.05 (-0.88%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close5.65
Open5.60
Bid0.00 x 0
Ask0.00 x 0
Day's Range5.50 - 5.70
52 Week Range4.20 - 9.80
Volume57,788
Avg. Volume130,909
Market Cap141.602M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-1.61
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.50
Trade prices are not sourced from all markets
  • PR Newswire22 days ago

    Intec Pharma Names R. Michael Gendreau, M.D., Ph.D. as Chief Medical Officer

    JERUSALEM, Jan. 31, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (NTEC), a clinical stage biopharmaceutical company focused on developing pharmaceutical therapies based on its proprietary Accordion Pill™ platform technology, today announced it has named R. Michael Gendreau, M.D., Ph.D. to the position of Chief Medical Officer. Dr. Gendreau, a seasoned industry veteran, brings to Intec Pharma over 30 years of experience in the drug development and pharmaceutical industry.

  • PR Newswirelast month

    Intec Pharma Announces Development Collaboration With Global Pharmaceutical Company

    Intec Pharma Ltd. (NTEC) (NTEC.TA), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, today announced it has entered into a Feasibility and Option agreement with Novartis Pharmaceuticals to explore using the Accordion Pill platform for a proprietary Novartis compound. Following potentially successful feasibility studies including a Phase 1 PK study, Novartis has the option to enter into negotiations with respect to a potential licensing agreement for employing Intec Pharma Accordion Pill™ technology. "We are delighted to work with Novartis in potentially utilizing our Accordion Pill platform technology," said Jeffrey A. Meckler, Chief Executive Officer of Intec Pharma.

  • Investopedia2 months ago

    Pot Stock Winners of the Week

    Despite the cannabis sector taking a beating last week, these four stocks rose more than 5%.

  • PR Newswire2 months ago

    Intec Pharma Granted Patent in Canada for Accordion Pill™ Carbidopa / Levodopa

    Intec Pharma Ltd. (NTEC) (NTEC.TA), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion PillTM platform technology, today announced that the Canadian Intellectual Property Office has issued a Certificate of Grant of a Canadian patent No. 2,721,493. The patent, entitled "Carbidopa/Levodopa Gastroretentive Drug Delivery," broadly covers the Accordion Pill containing certain drugs, including the combination of Carbidopa and Levodopa and provides patent protection through April 2029. The patent belongs to the Company's IN-7 patent family, which already includes patents granted in the U.S., Europe, China, Japan, South Korea, Hong Kong, South Africa, and Israel.

  • PR Newswire3 months ago

    Intec Pharma Reports Third Quarter 2017 Operating and Financial Results

    · Closed equity offering of $57.5 million ; Cash of $64.7 million at September 30, 2017 · Expanding planned enrollment to 420 patients in its Phase 3 ACCORDANCE Trial; enrollment to be completed in the ...

  • PR Newswire3 months ago

    Intec Pharma, Ltd. to Present at the Jefferies 2017 London Healthcare Conference

    JERUSALEM , November 8, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ, TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform ...

  • PR Newswire4 months ago

    Intec Pharma, Ltd. Announces Changes to its Board of Directors

    Intec Pharma Ltd. (NASDAQ, TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, today announced that Mr. Zvi Joseph, founder and Mr. Giora Carni, former CEO of Intec Pharma, will step down from their roles as Directors on the Board of Intec Pharma, and plan to serve as advisors to the Company going forward. "Zvi and Giora have been instrumental in the founding and early development of the Company, and we are pleased that they are remaining on as trusted advisors.

  • PR Newswire4 months ago

    Intec Pharma Ltd. Announces Changes to its Board of Directors

    Intec Pharma Ltd. (Nasdaq, TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, today announced that Mr. Zvi Joseph, founder and Mr. Giora Carni, former CEO of Intec Pharma, will step down from their roles as Directors on the Board of Intec Pharma, and plan to serve as advisors to the Company going forward. "Zvi and Giora have been instrumental in the founding and early development of the Company, and we are pleased that they are remaining on as trusted advisors.

  • PR Newswire4 months ago

    Intec Pharma Names Walt Linscott as Chief Administrative Officer

    Intec Pharma Ltd. (NTEC) (NTEC.TA), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, today announced it has named Mr. Walt Linscott to the position of Chief Administrative Officer. Mr. Linscott brings to Intec three decades of global leadership, entrepreneurial and professional experience with broad business development, operational, regulatory, and transactional experience in the Life Sciences sector.

  • PR Newswire5 months ago

    Intec Pharma to Participate in the Oppenheimer Specialty Pharma Summit

    JERUSALEM , October 6, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced that management will participate in the Oppenheimer Specialty Pharma Summit to be held October 11, ...

  • Investopedia5 months ago

    Pot Stock Winners of the Week

    Zynerba had a phenomenal week of trading off positive results from a cannabinoid-based drug trial.

  • Investopedia5 months ago

    Pot Stock Winners of the Week

    Notable gainers this week include Intec Pharma.

  • PR Newswire5 months ago

    Intec Pharma to Participate in the Ladenburg Thalmann 2017 Healthcare Conference

    JERUSALEM , September 20, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced that management will participate in the Ladenburg Thalmann 2017 Healthcare Conference to be held ...

  • PR Newswire5 months ago

    Intec Pharma to Participate in the 19th Annual Rodman & Renshaw Global Investment Conference

    JERUSALEM , September 8, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced that management will participate in the 19th Annual Rodman & Renshaw Global Investment Conference ...

  • PR Newswire6 months ago

    Intec Pharma to Participate in BioCentury's 24th Annual NewsMakers in the Biotech Industry Conference

    JERUSALEM , September 1, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced that management will participate in BioCentury's 24th Annual NewsMakers in the Biotech Industry Conference ...

  • Intec Pharma (NTEC) Catches Eye: Stock Adds 9.8% in Session
    Zacks6 months ago

    Intec Pharma (NTEC) Catches Eye: Stock Adds 9.8% in Session

    Intec Pharma Ltd. (NTEC) moved big last session, as its shares rose more than 9% on the day.

  • PR Newswire6 months ago

    Intec Pharma Announces Closing of $57.5 Million Public Offering of Ordinary Shares

    Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced the closing of its previously announced offering of approximately 12.2 million of its ordinary shares, at a public offering price of $4.70 per ordinary share, which included a full exercise by the underwriters of their over-allotment option in the amount of 1,594,500 ordinary shares, for gross proceeds of approximately $57.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses. Oppenheimer & Co. Inc. acted as the sole book-running manager, Roth Capital Partners acted as lead manager, and Maxim Group LLC acted as co-manager in the offering. Intec Pharma intends to use the net proceeds from this offering to fund its Phase III clinical trial for Accordion Pill Carbidopa/Levodopa, the company's leading product candidate for the indication of treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients, for working capital and for general corporate purposes.

  • PR Newswire6 months ago

    Intec Pharma Announces Pricing of $50.0 Million Public Offering of Ordinary Shares

    Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced the pricing of an underwritten public offering of approximately 10.6 million of its ordinary shares at a public offering price of $4.70 per ordinary share. Intec Pharma has granted the underwriters a 30-day option to purchase up to approximately 1.6 million additional ordinary shares to cover over-allotments. Intec Pharma intends to use the net proceeds from this offering to fund its Phase III clinical trial for Accordion Pill Carbidopa/Levodopa, the company's leading product candidate for the indication of treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients, for working capital and for general corporate purposes.

  • PR Newswire6 months ago

    Intec Pharma Announces Proposed Public Offering of Ordinary Shares

    Intec Pharma Ltd. (NTEC) (NTEC.TA) today announced the launch of an underwritten public offering of its ordinary shares. In connection with this offering, Intec Pharma also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of ordinary shares being offered to cover over-allotments. All ordinary shares in the offering are being offered by Intec Pharma.

  • PR Newswire6 months ago

    Intec Pharma Reports Financial Results for the First Six Months of 2017

    JERUSALEM , Aug. 9, 2017 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC) (TASE: NTEC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ (AP) ...

  • PR Newswire7 months ago

    Intec Pharma Reports Clinical Results From Phase I Trial of Accordion Pill for Cannabinoid Therapies

    Intec Pharma Ltd. (NTEC) (NTEC.TA), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces the results from a Phase I clinical trial of AP-CBD/THC, its Accordion Pill platform with cannabidiol (CBD) and tetrahydrocannabinol (THC), the two primary cannabinoids contained in Cannabis sativa. "We're excited about these encouraging results from our Phase 1 study of AP-CBD/THC as it shows the Accordion Pill platform is well suited to safely deliver CBD and THC with significant improvements in exposure compared with Sativex®," said Nadav Navon, Ph.D., Chief Operating Officer of Intec Pharma. The Phase I trial was a single-center, single-dose, randomized, three-way crossover study to compare the pharmacokinetics, safety and tolerability of two formulations of AP-CBD/THC with Sativex in 21 normal healthy volunteers.

  • PR Newswire7 months ago

    Intec Pharma Promotes Nadav Navon, Ph.D. to Chief Operating Officer

    Intec Pharma Ltd. (Nasdaq, TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ (AP) platform technology, announces the promotion of Nadav Navon, Ph.D., Executive Vice President-Research & Development and Operations to Chief Operating Officer, effective immediately. "Dr. Navon has been instrumental in the growth and development of Intec Pharma since he joined the team in 2006.

  • PR Newswire7 months ago

    Intec Pharma Granted Patent in Hong Kong for Accordion Pill™ Carbidopa / Levodopa

    Intec Pharma Ltd. (NASDAQ, TASE: NTEC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill[TM] platform technology, announces that the Patent Registry Intellectual Property Department of Hong Kong has issued a Certificate of Grant of a Hong Kong patent for an Accordion Pill containing certain drugs, including the combination of Carbidopa and Levodopa. The patent, granted under No. HK1158545, is titled "Carbidopa/Levodopa Gastroretentive Drug Delivery" and is currently scheduled to remain in force until April 2029. The patent belongs to the Company's IN-7 patent family, which already includes patents granted in the U.S., Europe, China, Japan, South Korea, South Africa and Israel.

  • PR Newswire7 months ago

    Intec Pharma Appoints U.S. Life Sciences Executive and Vice Chairman Jeffrey A. Meckler as Chief Executive Officer

    Intec Pharma Ltd. (Nasdaq: NTEC, TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces the appointment of Jeffrey A. Meckler as Chief Executive Officer, effective immediately. Mr. Meckler was named Vice Chairman of the Intec Pharma Board of Directors in April 2017 and will continue in that role. Giora Carni, a Director since 2006 who has served as Interim Chief Executive Officer since May 2017, will continue to serve on the company's Board.

  • Investopedia8 months ago

    Pot Stock Winners of the Week

    These three companies popped this week, but one is a highly volatile penny stock.